The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

11 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthesis and biological activity of CCK26-33-related analogues modified in position 31.EBI
University Of Paris
Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors.EBI
TBA
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.EBI
Merck Sharp & Dohme Research Laboratories
 
Cholecystokinin analogues: The ergopeptine alkaloids as models of the active conformation of CCKEBI
TBA
Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.EBI
Merck
 
Synthesis and pharmacological evaluation of highly potent dual histamine H2 and gastrin receptor antagonistsEBI
TBA
 
Design, synthesis, and pharmacological evaluation of dual histamine H2 and gastrin receptor antagonistsEBI
TBA
 
Novel cholecystokinin receptor ligands: Oxopiperazines derived from Boc-CCK-4EBI
TBA
2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.EBI
Merck
Pharmacological treatment of obesity: therapeutic strategies.EBI
The R. W. Johnson Pharmaceutical Research Institute
Investigation of peripheral cholecystokinin receptor heterogeneity by cyclic and related linear analogues of CCK26-33: synthesis and biological properties.EBI
TBA